Angiotensin-converting enzyme (ACE) Inhibitors and angiotensin receptor blockers (ARBs): These medications are prescribed in the early phase of STEMI to reduce ventricular remodeling, improve cardiac function, and prevent heart failure development.[1]. This evidence concerns the gene ACE and heart failure.